Cure My Disease

Don't miss your cure!

Home News Browse Soon ready About
Log in / Sign up
← Back to home

Liping Dou

Clinical trials sponsored by Liping Dou, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

  • New CAR-T therapy aims to keep leukemia in remission Results expected Dec 2026 (estimated)
  • New CAR-T therapy aims to keep High-Risk leukemia in remission Results expected Dec 2026 (estimated)
  • Engineered immune cells aim to deepen remission in lymphoma patients Results expected Jan 2027 (estimated)
  • Can engineered immune cells lock in remission for aggressive lymphoma? Results expected Apr 2027 (estimated)
Browse trials soon ready across all sponsors →
Trials to join now! 5 Not yet recruiting 1 Not yet finished but already full! 2
Sort by
  • In-Body CAR-T therapy takes aim at Hard-to-Treat blood cancer

    Disease control Not yet recruiting

    This early-phase study tests the safety of a new immunotherapy that creates cancer-fighting cells inside the body for people with relapsed or refractory plasma cell neoplasms, a type of blood cancer. The treatment targets two proteins (BCMA and GPRC5D) on cancer cells. Researcher…

    Early phase 1 • Sponsor: Liping Dou • Aim: Disease control

    Last updated Jun 27, 2026 12:33 UTC

Cure My Disease

Helping patients find clinical trials that match their disease.

Why was Cure my disease built?

Explore

Home News Browse Glossary About Terms of use Contact us

This is a site from Cyber and Space